Brain Tumor Therapeutics

Malignant brain tumors are the second-leading cause of cancer-related deaths in children and young adults. The foundation of brain tumor therapeutics research conducted at the Falk Center is systems-based gene discovery, which leads to the design of therapeutic strategies and culminates with FDA approval for clinical trials.

The Brain Tumor Therapeutics Program

1. Gene Discovery

Novel Therapeutic StrategyOur integrative systems biology-based ‘omics’ approach to understand primary and metastatic brain tumorigenesis includes:

  • genomics to assess chromosomal abnormalities
  • transcriptomics to assess changes in mRNA abundance
  • proteomics (both global and phospho) to assess protein and intracellular signaling changes
  • glycomics to assess changes in cell surface glycosylation
  • metabolomics to assess alterations in intracellular metabolism

2. Therapeutics Design

Bioinformatics-based integration of the systems data identifies critical targets and gene networks for the development of therapeutic strategies that are directly assessed for efficacy in multiple in vitro and in vivo preclinical model systems.

3. FDA Approval Clinical Trials

We have identified and created multiple adenoviral-based gene therapies for clinical trials.